产品
编 号：F361027
分子式：C27H19F3N4O3
分子量：504.46
分子式：C27H19F3N4O3
分子量：504.46
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 450839-40-4
产品详情
生物活性：
ABT-100 is a potent, highly selective and orally active farnesyltransferase inhibitor. ABT-100 inhibits cell proliferation (IC50s of 2.2 nM, 3.8 nM, 5.9 nM, 6.9 nM, 9.2 nM, 70 nM and 818 nM for EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells, respectively), increases apoptosis and decreases angiogenesis. ABT-100 possesses broad-spectrum antitumor activity.
体内研究：
ABT-100 (6.25-12.5 mg/kg/天；皮下注射；每天；持续 21 天；CB-17 scid 雄性小鼠) 处理使小鼠的 EJ-1 肿瘤消退。Animal Model:C.B-17 scid male mice with EJ-1 cells
Dosage:6.25 mg/kg/day, 12.5 mg/kg/day
Administration:Subcutaneous injection; daily; for 21 days
Result:Regressed EJ-1 tumors in C.B-17 scid male mice.
体外研究：
ABT-100 (0.1-100 nM；7 天；EJ-1、DLD-1、MDA-MB-231、HCT-116、MiaPaCa-2、PC-3 和 DU-145 细胞) 处理显示剂量依赖性生长抑制人类癌细胞系。在与 ABT-100 抑制贴壁依赖性生长的浓度相当的情况下，也可抑制集落形成。
ABT-100 is a potent, highly selective and orally active farnesyltransferase inhibitor. ABT-100 inhibits cell proliferation (IC50s of 2.2 nM, 3.8 nM, 5.9 nM, 6.9 nM, 9.2 nM, 70 nM and 818 nM for EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells, respectively), increases apoptosis and decreases angiogenesis. ABT-100 possesses broad-spectrum antitumor activity.
体内研究：
ABT-100 (6.25-12.5 mg/kg/天；皮下注射；每天；持续 21 天；CB-17 scid 雄性小鼠) 处理使小鼠的 EJ-1 肿瘤消退。Animal Model:C.B-17 scid male mice with EJ-1 cells
Dosage:6.25 mg/kg/day, 12.5 mg/kg/day
Administration:Subcutaneous injection; daily; for 21 days
Result:Regressed EJ-1 tumors in C.B-17 scid male mice.
体外研究：
ABT-100 (0.1-100 nM；7 天；EJ-1、DLD-1、MDA-MB-231、HCT-116、MiaPaCa-2、PC-3 和 DU-145 细胞) 处理显示剂量依赖性生长抑制人类癌细胞系。在与 ABT-100 抑制贴壁依赖性生长的浓度相当的情况下，也可抑制集落形成。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备